Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
8th FENS Forum of Neuroscience
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Remyelination therapy goes to trial for multiple sclerosis
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
American Society for Cell Biology Annual Meeting
Predictive value of early brain atrophy on response in patients treated with interferon β.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Microglia activation is associated with IFN-α induced depressive-like behavior.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.

Pages